FDA Fast-Tracks Zika Blood Tests with Class II Safety Nod
Published Date: 5/29/2025
Rule
Summary
The FDA is officially putting Zika virus blood test tools into a special safety group called Class II. This means these tests will have clear rules to keep them safe and working well, helping patients get better access to these important tools faster. This change affects companies making these tests and aims to cut down on red tape without costing extra time or money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Zika serology reclassified to Class II
The FDA is classifying Zika virus serological reagents as Class II devices with special controls. The agency says this classification provides a reasonable assurance of the tests' safety and effectiveness. The action is intended to enhance patients' access to these tests by reducing regulatory burdens.
Reduced regulatory burden for test makers
The FDA says moving Zika virus serological reagents into Class II will reduce regulatory burdens for companies that make these tests. The classification aims to enhance access without adding extra time or cost for the industry.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-09638, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Plazomicin Test System
The FDA is officially putting the plazomicin test system into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get access to this cool new medical tool faster. If you make or use these tests, get ready for some updated guidelines that balance safety with easier approval.
Next: 2025-09640, Medical Devices; Gastroenterology-Urology Devices; Classification of the Temporarily-Placed Urethral Opening System for Symptoms of Benign Prostatic Hyperplasia
The FDA is officially classifying a new device that helps with urinary problems caused by an enlarged prostate as a Class II device with special safety rules. This means the device will be safer and easier to get for patients who need it. The change helps companies bring this helpful device to market faster without extra red tape.